- Report
- September 2023
- 180 Pages
Global
From €5752EUR$5,950USD£4,941GBP
- Report
- March 2024
- 168 Pages
Global
€4829EUR$4,995USD£4,148GBP
- Report
- May 2020
- 194 Pages
Global
From €1924EUR$1,990USD£1,653GBP
- Report
- January 2018
- 618 Pages
Global
From €21269EUR$22,000USD£18,269GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£830GBP
Sovaldi is a prescription drug used to treat chronic hepatitis C virus (HCV) infection. It is a nucleotide analog inhibitor, which works by blocking the virus from replicating in the body. Sovaldi is the first drug of its kind to be approved by the US Food and Drug Administration (FDA) for the treatment of HCV. It is also the first drug to be approved for the treatment of all six major genotypes of HCV.
Sovaldi is part of a larger market of infectious diseases drugs, which are used to treat a variety of bacterial, viral, and fungal infections. These drugs are used to treat a wide range of conditions, from common colds to more serious illnesses such as HIV/AIDS and tuberculosis.
The Sovaldi market is highly competitive, with many companies offering similar products. Some of the major players in the market include Gilead Sciences, AbbVie, Merck, Bristol-Myers Squibb, and Pfizer. These companies are constantly innovating and developing new drugs to treat infectious diseases. Show Less Read more
